Rumors of a buyout sent Biogen Idec (NASDAQ:BIIB) shares up about $13 to over $82 per share.
I first recommended BIIB last year at $44.6 based on the potential success of Tysabri in treating MS (link to that article). As of Tuesday's price, the stock is up 84% and I am recommending to sell and to take any profits as I believe a buyout is far from certain and any changes to these speculations will send the stock back down to $70.
Buying at these levels is definitely not recommended since the price is way too expensive based on fundamentals.
BIIB 1-yr chart:
Disclosure: The author does not have a position in BIIB at this time.